Funding news
Mirxes Hong Kong logo

Mirxes Hong Kong Raises $91

Recently funded · $910.0M Series dHospitals and Health CareHKView source

Get the full Mirxes Hong Kong company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Mirxes Hong Kong, a company championing a shift towards preventive medicine, has successfully closed its Series D funding round, raising a substantial $910.0M. The Singapore-headquartered firm, which maintains operational teams across mainland China, Japan, the US, and Hong Kong, extends its reach to over 45 countries globally.

The company's core mission revolves around leveraging continuous scientific innovation to provide high-quality solutions in preventive medicine, believing that the future of healthcare lies in early detection and prevention rather than solely in treatment.

Other Hong Kong companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series d rounds

Companies that recently closed a Series d round.

#CompanyAmount
1
Xactly Corp logo

Xactly Corp

United States

$56.3M
2
Rapid7 logo

Rapid7

United States

$30.0M
3
Agentforce Commerce logo

Agentforce Commerce

United States

$15.0M
4
Valens Semiconductor logo

Valens Semiconductor

Israel

$60.0M
5
Waterdrop logo

Waterdrop

United States

$230.0M